Reducing the variability associated with inhaler testing, notably cascade impaction testing, is a critical, ongoing activity for the industry. Experience suggests that the complete automation of testing is not always the best solution due to the complexity, risk and investment involved. Rather, best practice centers on semi-automation, the use of proven, modular, easy-to-validate automation solutions integrated within a wider variability reduction strategy. Such solutions not only reduce the variability associated with testing but, at the same time, increase analytical throughput, boosting operator morale and productivity. As a result, they can offer an attractive return on investment, alongside the much greater prize of substantially enhanced data quality and integrity.
Optimizing the role of automation in variability reduction strategies for delivered dose uniformity (DDU) and aerodynamic particle size distribution (APSD) testing of inhaled drug products
Semi-automation can enhance the quality of inhaler test data, while at the same time boosting productivity; choosing which tasks to automate and appropriate technology is essential.